CAJ | 학술논문

目的：探讨钠-葡萄糖共转运蛋白-2（ SGLT-2）抑制剂的药理学作用与临床应用。方法：采用文献分析方法，对国内外SGLT-2抑制剂相关文献进行检索，评价SGLT-2抑制剂的临床疗效与安全性。结果与结论：SGLT-2抑制剂为一类新型抗糖尿病药，临床上用于饮食和运动控制治疗后效果不佳的2型糖尿病者。 SGLT-2抑制剂的作用机制与口服降糖药截然不同，其非在于促进胰岛β细胞分泌胰岛素，作用不依赖胰岛素，可延缓糖尿病的进程，发生低血糖的风险小，具有良好的应用前景，但其安全性、经济性、临床获益有待更长期的临床研究来证明。
목적：탐토납-포도당공전운단백-2（ SGLT-2）억제제적약이학작용여림상응용。방법：채용문헌분석방법，대국내외SGLT-2억제제상관문헌진행검색，평개SGLT-2억제제적림상료효여안전성。결과여결론：SGLT-2억제제위일류신형항당뇨병약，림상상용우음식화운동공제치료후효과불가적2형당뇨병자。 SGLT-2억제제적작용궤제여구복강당약절연불동，기비재우촉진이도β세포분비이도소，작용불의뢰이도소，가연완당뇨병적진정，발생저혈당적풍험소，구유량호적응용전경，단기안전성、경제성、림상획익유대경장기적림상연구래증명。
OBJECTIVE:To explore the pharmacology of and clinical evaluation about sodium glucose co transporter 2 (SGLT-2) Inhibitors. METHODS:By reviewing pertinent literature both at home and abroad about the related articles of sodium-glucose cotransporter-2 to evaluate the pharmacology of and clinical evaluation. RESULTS & CONCLUSIONS:Sodium-glucose cotransporter-2 inhibitor is completely different form oral hypoglycemic agent in the mechanism of action in that its action doesn’t rely on the promotion of pancreaticβ-cell to secrete insulin nor dependent on insulin, however, it can delay the progression of diabetes and lower the risk of hypoglycaemia, which thus has a good application prospect,but it’s safety,economy and the clinical benefit need more long-term clinical studies to prove.